Hematologic Malignancy
Hairy Cell Leukemia Variant
CI-CAN-00002799HCL-V · SBLPNExplore in graph →
Hematologic4 active trials
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00002799HCL-V · SBLPNExplore in graph →
Clinical trials
4 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (0)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01841723 | Ibrutinib in Treating Patients With Relapsed Hairy Cell Leukemia | active not recruiting | Phase 2 | 44 | National Cancer Institute (NCI)NIH | 1 | Sep 15, 2026 | clinicaltrials |
| NCT06311227 | Venetoclax for the Treatment of Patients With Relapsed Hairy Cell Leukemia | active not recruiting | Phase 2 | 20 | National Cancer Institute (NCI)NIH | 1 | Sep 9, 2026 | clinicaltrials |
| NCT07690761 |
| Rituximab+ Zanubrutinib for Patients With Hairy Cell Leukemia and Hairy Cell Variant(Rituximab+ Zan) |
| enrolling by invitation |
| Phase 2 |
| 12 |
| Bnai Zion Medical CenterOTHER_GOV |
| 1 |
| Jul 8, 2026 |
| clinicaltrials |
Data updated 15 days agoSource updated Sep 15, 2026source: clinicaltrials